A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples
This trial is active, not recruiting.
|Condition||carcinoma, non-small-cell lung|
|Sponsor||Peking Union Medical College Hospital|
|Collaborator||Peking University People's Hospital|
|Start date||June 2010|
|Trial size||150 participants|
|Trial identifier||NCT01382992, LCC001|
EGFR mutations plays an essential role in EGFR-TKIs treatment. However, for some patients, tissue samples are not available. The purpose of this study is to determine whether blood sample is feasible for EGFR mutation detection.For late stage NSCLC, we hypothesis plasma sample is an alternative for detecting EGFR mutations.
To determine the consistence of EGFR mutation status in paired tissue and plasma samples
time frame: 3 months
To determine the EGFR mutation status in Chinese NSCLC
time frame: 3month
Male or female participants at least 18 years old.
Inclusion Criteria: - Non-small cell lung cancer - Available plasma and pathologically confirmed tissue slices(pre-chemo and pre-radio therapy) - Informed Consent Exclusion Criteria: - N/A
|Principal investigator||Mengzhao Wang, MD|
Call for more information